Rekombinanter CPA1 Antikörper (full length)

Produktnummer ABIN7877799

Der Kaninchen Monoklonal anti-CPA1 Antikörper wird verwendet zum Nachweis von CPA1 in Proben von Human. Er wurde validiert für IHC (p).

Kurzübersicht für Rekombinanter CPA1 Antikörper (full length) (ABIN7877799)

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser CPA1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: CPA1-8259R

Produktdetails anti-CPA1 Antikörper

Bindungsspezifität: full length

Verwendungszweck: CPA1 Antibody / Carboxypeptidase A1

Aufreinigung: Protein A/G affinity

Immunogen: Recombinant full-length human CPA1 protein was used as the immunogen for the CPA1 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the CPA1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the CPA1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu CPA1

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Andere Bezeichnung: CPA1

Hintergrund: Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.

UniProt: P15085